New York Harbor VA Brooklyn Campus
Brooklyn, New York, 11209, United States
Location status: Recruiting
NCT Number: NCT06952517
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
Brooklyn, New York, 11209, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clascoterone 1% cream
Other names: WINLEVI
Time frame: From enrollment to end of treatment at 12 weeks
We will perform both a paired and pooled statistical analysis. We will conduct a power analysis to determine statistical significance. For the paired analysis, we will calculate the average gland size per patient at baseline and again at the end of the treatment period from all the individual's biopsy sites. We will then calculate the percent reduction of sebaceous gland size between the two average sizes. Finally, we will calculate the average percent change across all participants.
For the pooled analysis, we will calculate the average sebaceous gland size across all study participants before and after treatment. We will use these two values to calculate the percent change. We anticipate that the paired analysis will yield more meaningful results as the pooled analysis may not show significant change due to the variations between study participants used to calculate the averages.
Time frame: From enrollment to end of treatment at 12 weeks
We plan to calculate the incidence of adverse events. Study participants will be instructed to keep a log of all adverse events.
Time frame: From enrollment to end of treatment at 12 weeks
Pre- and post-treatment digital photography with a camera (Canfield Scientific, Parsippany, NJ) to depict clinical improvement of rosacea.
Time frame: From enrollment to end of treatment at 12 weeks
A modified, succinct version of the Rosacea clinical scorecard as proposed by the Report of the National Rosacea Society Expert Committee on the Classification and Staging of sRosacea will be used to assess these measures. Physicians and study participants will be asked to grade the rosacea at baseline and at the end of the treatment based on the following scale:
Contact information is provided by the study sponsor or research team.
Narrows Institute for Biomedical Research
Other
Efficacy and Safety of Topical Clascoterone Cream 1% in Patients With Facial Acneiform Rosacea
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00882531
Papular-pustular Rosacea
View Trial DetailsNCT07681271
Papulopustular Rosacea, Primary hyperoxaluria type 2
El Paso, Texas, United States
View Trial DetailsNCT05296629
Papulopustular Rosacea, Rosacea
Rogers, Arkansas, United States
View Trial DetailsNCT05343455
Papulopustular Rosacea, Rosacea
Santa Monica, California, United States
View Trial Details